Product Reports Resources Pricing Login Book a demo

Taxon Biosciences

Biotech & Life Sciences · Tiburon, United States · Founded 2000

Microbial structures for transformative apps in the agriculture, life sciences, and oil and gas industries MoreLess

Taxon Biosciences, founded in 2000 by microbial geneticists Matt Ashby and Jasper Rine, operated as a biotechnology firm specializing in microbial genomics. The company was established with the goal of creating a microbial genomics platform to address significant challenges in the agriculture, energy, and health science sectors. Based in Tiburon, California, Taxon Biosciences focused on utilizing proprietary advancements in genomics, bioinformatics, and microbiology. Its core business involved identifying, validating, and commercializing microbiome-based products derived from agricultural and environmental settings.

The company's primary service was to profile microbial communities using genomic tools to understand their structure and function. This involved conducting in-depth diversity profiles of selected sites to identify specific DNA sequences correlated with parameters of interest, such as the presence of certain gases or salinity levels. From this data, the firm developed quantitative assays for these indicator species, which could then be used in broader bioindicator surveys. The business catered to a range of markets, including the energy sector and clinical diagnostics. Its technology and extensive intellectual property portfolio in microbial consortia and genomics were geared towards developing new products like seed treatments, as well as foliar and soil applications for major row crops, fruits, and vegetables.

A significant milestone in the company's history was its acquisition by DuPont in April 2015 for an undisclosed sum. This acquisition was a strategic move by DuPont to enhance its in-house capabilities in biological solutions for the agriculture industry, complementing its existing seed and crop protection businesses. Prior to the acquisition, Taxon Biosciences had secured $4.01 million in a Series A funding round in April 2013, with investors including Formation 8, BP Ventures, and ConocoPhillips Technology Ventures. The integration into DuPont was intended to accelerate the discovery-to-market timeline for new biological products.

Keywords: microbial genomics, microbiome discovery, bioinformatics, crop biologicals, agricultural biotechnology, seed treatment, soil health, microbial consortia, genomics platform, environmental microbiology, bioindicator surveys, microbial diversity, industrial microbiome, agtech, biological solutions, crop protection, plant health, sustainable agriculture, DuPont acquisition, Matt Ashby, Jasper Rine

Talent graph

Taxon Biosciences's talent

Book a demo to see the people
Team profiled 7 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 4 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Investors

2 investors on Taxon Biosciences's cap table

Sourced from Dealroom's funding and investor records.

Series A 2 investors entered at this stage
BP Global
BP Ventures

Global footprint

Where Taxon Biosciences has talent and traffic

Workforce by country
🇺🇸 United States · Tiburon HQ
Book a demo for the full country breakdown

Market sentiment

What the market is saying about Taxon Biosciences

An AI-synthesized read of the highest-engagement posts about Taxon Biosciences on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Taxon Biosciences on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.